Russian Pharmaceutical Company NovaMedica Announces the Opening of Its US
*NovaMedica is a new pharmaceutical company, established as an integral
part of the $760 million USD collaboration between the Russian
high-technology investment fund RUSNANO and the American health care
venture fund Domain Associates LLC.
*NovaMedica was formed specifically to be the development, marketing and
operational arm, taking the highly innovative next-generation products
from the collaboration, and commercializing them in Russia and the CIS.
MOSCOW -- November 12, 2012
NovaMedica, a company whose mission is to commercialize highly innovative
pharmaceutical products in Russia and the CIS, today announces the opening of
its US office.
NovaMedica is a newly established pharmaceutical company created by the Domain
Associates, a leading US life sciences venture capital firm and RUSNANO, a
Russian high-technology investment fund. The partners have committed to invest
in emerging companies, developing innovative pharmaceuticals, devices, and
diagnostics, and bring these products to the markets in Russia and the
Community of Independent States (CIS). The total budget of the program is $760
Million USD, and includes the creation of a state of the art manufacturing
facility. NovaMedica was formed to exclusively commercialize the highly
innovative products coming from this partnership that have significant value
in the Russian market.
“With many products set to move into NovaMedica from the Domain family of
companies, we believe NovaMedica is uniquely positioned to facilitate
innovative drug development and accelerate corporate growth. Our company is
simply the partner of choice for Russia and CIS”, - said COO, Pharmaceutical
Director and board member of NovaMedica Fabrice Egros, - “The opening of the
US office will allow for efficient and rapid interactions with our current and
Headquartered in Moscow (Russia), the new US office has been established in
Princeton, New Jersey.
Mary Anderson will lead the company's business development efforts in the US
Ms. Anderson has over 22 years of international licensing and business
development experience, in-licensing innovative products at all stages of
clinical development as well as marketed products. Prior to coming to
NovaMedica, Ms. Anderson’s experience included five years as Head of Licensing
and business development for the oncology division of Merck KGaA, the global
pharmaceutical and chemical company. She also played an integral role in
Merck's €10.6 billion purchase of Serono, the biotech firm headquartered in
Geneva Switzerland. Prior to Merck KgaA, Ms. Anderson held various business
development positions including serving ten years at Bayer AG headquartered in
Leverkusen, Germany, in various capacities related to business development,
strategic planning, and research. Ms. Anderson earned her BA in Biochemistry
from California State Polytechnic University, San Luis Obispo, California, USA
and her MBA from St. Mary’s University, Moraga, California, USA.
RUSNANO was established in March 2011 as an open joint stock company through
the reorganization of the state corporation Russian Corporation of
Nanotechnologies. RUSNANO's mission is to develop the Russian nanotechnology
industry through co-investment in nanotechnology projects with substantial
economic potential or social benefit. The Government of the Russian Federation
owns 100 percent of the shares in RUSNANO.
About Domain Associates
Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an
exclusive focus on life sciences. With $2.4 billion of capital under
management, Domain is headquartered in Princeton, NJ with a second office in
San Diego, CA. Domain’s three major investment segments are pharmaceuticals,
specialty pharmaceuticals, and medical devices, while additional areas of
interest include biomaterials, bioinstrumentation, and diagnostics.
Mary L. Anderson, +1 609-683-5656
Vice President, Business Development
Press spacebar to pause and continue. Press esc to stop.